$BABY (Natus Medical Inc.)

$BABY {{ '2016-10-19T16:28:08+0000' | timeago}} • Announcement

$BABY now expects its recently announced acquisition of Otometrics to close on Jan. 1, 2017. With Otometrics next year, $BABY looks forward to achieving $500MM in revenue. $BABY expects Otometrics to add to its 2017 earnings with a non-GAAP contribution operating margin goal for the year of 10% and a 2018 goal of 20%.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$SYK {{ '2018-01-09T17:21:37+0000' | timeago}} • Announcement

$SYK said that for 4Q17 its preliminary results are of net sales growth of 10% to $3.5Bil, while for FY17, its net sales grew 9.9% to $12.4Bil. Excluding the impact of foreign currency & acquisitions, net sales rose 8.1% and 7.1% in 4Q17 and FY17. For 2018, $SYK expects modest headwinds that will be manageable within its overall financial targets.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$BABY {{ '2018-01-08T12:48:13+0000' | timeago}} • Announcement

$BABY said that for FY18, the company expects revenue of $535-540MM and non-GAAP EPS of $1.60-1.65. For 1Q18, the company expects revenue of $125-127MM and non-GAAP EPS of $0.23-0.24. For 4Q17, $BABY expects to report revenue of approx. $131-132MM, while for FY17 revenue is expected to be $500.5-501.5MM.

$BABY {{ '2018-01-05T14:35:34+0000' | timeago}} • Announcement

$BABY appointed Leslie McDonnell as VP and General Manager of its Newborn Care Business Unit. McDonnell will report to CEO Jim Hawkins, and will be responsible for leading and expanding Natus' newborn care business. McDonnell is expected to join Natus on Feb. 12, 2018.

$BABY {{ '2018-01-05T14:07:05+0000' | timeago}} • Announcement

$BABY has named Leslie McDonnell as Vice President and General Manager of its Newborn Care Business Unit. Ms. McDonnell will report to Jim Hawkins, CEO. She is expected to join $BABY on February 12, 2018.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CELG {{ '2017-12-22T14:11:59+0000' | timeago}} • Announcement

$CELG's cancer drug Revlimid fails to meet the endpoint in the first Phase 3 trial. Celgene said that additional analyses are ongoing and it would present the complete analyzed data in a future medical conference. Revlimid contributed 63% of Celgene's revenue in their recently ended third quarter.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$ABBV {{ '2017-12-21T13:23:43+0000' | timeago}} • Announcement

$ABBV announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

$ZBH {{ '2017-12-19T14:31:26+0000' | timeago}} • Announcement

$ZBH appointed Bryan Hanson as President and CEO and a member of the BoD, effective Dec. 19, 2017. Daniel Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as SVP and CFO. Most recently, Hanson served as a $MDT's Executive Committee member and as EVP and President of Medtronic's Minimally Invasive Therapies Group.

$MDT {{ '2017-12-19T14:11:39+0000' | timeago}} • Announcement

$MDT has named Bob White, previously SVP and President of APAC Region, as EVP and President of Minimally Invasive Therapies Group. The company also announced Chris Lee, SVP and President of Greater China Region, will assume the position of APAC Region President. These leadership changes are effective immediately.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
RMTI (Rockwell Medical, Inc.)
Wednesday, November 8 2017 - 9:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
ELMD (Electromed, Inc.)
Wednesday, November 8 2017 - 2:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
IRIX (IRIDEX Corporation)
Thursday, November 2 2017 - 9:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
VAR (Varian Medical Systems, Inc.)
Wednesday, October 25 2017 - 9:00pm
BABY (Natus Medical Inc.)
Wednesday, October 25 2017 - 3:00pm
BIIB (Biogen Inc.)
Tuesday, October 24 2017 - 12:30pm
NURO (NeuroMetrix Inc.)
Thursday, October 19 2017 - 12:00pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm
ELMD (Electromed, Inc.)
Wednesday, September 6 2017 - 1:00pm

AlphaGraphics you may like